Key Points
- Insider sale: Director Esther Rajavelu sold 40,270 shares at an average of $2.37 on Nov. 7 for $95,439.90, trimming her stake by 4.43% to 869,450 shares (worth about $2.06M).
- Mixed financials: Spero reported Q results that beat expectations (EPS -$0.03 vs. -$0.38 consensus; revenue $14.19M vs. $11.0M) but remains unprofitable with a negative net margin and a market cap near $150M.
- Market sentiment: Analysts have a consensus "Hold" rating with an average target of $5.00, and institutional ownership is about 25.6% amid recent position changes by several funds.
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 40,270 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $2.37, for a total value of $95,439.90. Following the sale, the insider owned 869,450 shares in the company, valued at $2,060,596.50. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Spero Therapeutics Stock Performance
Shares of SPRO traded up $0.01 during mid-day trading on Thursday, reaching $2.67. 280,539 shares of the company's stock traded hands, compared to its average volume of 1,568,380. Spero Therapeutics, Inc. has a 12 month low of $0.51 and a 12 month high of $3.22. The business's 50-day moving average price is $2.18 and its 200-day moving average price is $2.09. The stock has a market capitalization of $149.99 million, a P/E ratio of -2.72 and a beta of 1.55.
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.35. Spero Therapeutics had a negative net margin of 110.35% and a negative return on equity of 120.27%. The firm had revenue of $14.19 million for the quarter, compared to analysts' expectations of $11.00 million. Equities research analysts anticipate that Spero Therapeutics, Inc. will post -1.2 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts recently commented on SPRO shares. Zacks Research downgraded shares of Spero Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Spero Therapeutics in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Spero Therapeutics currently has a consensus rating of "Hold" and an average target price of $5.00.
Read Our Latest Stock Report on SPRO
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of SPRO. Anson Funds Management LP increased its position in Spero Therapeutics by 98.9% during the 1st quarter. Anson Funds Management LP now owns 7,638,818 shares of the company's stock worth $5,500,000 after buying an additional 3,798,932 shares during the period. Vanguard Group Inc. raised its holdings in shares of Spero Therapeutics by 2.0% in the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company's stock valued at $3,741,000 after purchasing an additional 39,474 shares during the last quarter. Mackenzie Financial Corp raised its stake in shares of Spero Therapeutics by 11.4% during the 1st quarter. Mackenzie Financial Corp now owns 209,031 shares of the company's stock worth $151,000 after purchasing an additional 21,472 shares during the period. Stonepine Capital Management LLC purchased a new stake in Spero Therapeutics in the 2nd quarter worth about $455,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Spero Therapeutics in the third quarter worth $201,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.
Spero Therapeutics Company Profile
(
Get Free Report)
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
